Novo Nordisk plans to make bariatric surgery a thing of the past: The key is not one but two drugs
Combinations of at least two different drugs have become an important element of Novo Nordisk's future plans within obesity, fatty liver disease and diabetes. One combination in particular looks set to become a top product, says chief science officer.
BY KEVIN GRØNNEMANN, TRANSLATED BY IDA JACOBSEN
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.